# Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

> **NCT01990469** · PHASE3 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 219 (actual)

## Conditions studied

- T2DM

## Interventions

- **DRUG:** Gemigliptin
- **DRUG:** Gemigliptin placebo

## Key facts

- **NCT ID:** NCT01990469
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01990469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01990469, "Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01990469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*